Status:
UNKNOWN
Pharmacogenetics in Non Small Cell Lung Cancer
Lead Sponsor:
Ain Shams University
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Study the effect of genetic polymorphism in the membrane copper transporter 1 protein \[CTR1; encoded by the solute carrier family 31 member 1 gene (SLC31A1 gene)\] and its genetic expression levels o...
Detailed Description
The cisplatin-based regimen is an effective treatment for advanced NSCLC, showing significant beneficial outcomes such as prolong survival, improve clinical symptoms, and improve quality of life (QOL)...
Eligibility Criteria
Inclusion
- Newly diagnosed with immunohistochemically and pathologically confirmed non- small cell lung cancer (NSCLC).
- ECOG PS 0-2.
- Chemotherapy naïve.
- Age \>18 years.
- Adequate bone marrow reserve.
Exclusion
- Presence of central nervous system metastases.
- Inadequate liver function (bilirubin \> 1.5 times upper normal limit \[ULN\] and alanine transaminase \[ALT\] or aspartate transaminase \[AST\] \> 3.0 ULN or up to 5.0 UNL in the presence of hepatic metastases).
- Inadequate renal function (creatinine \> 1.25 times ULN, creatinine clearance \< 50mL/min).
- Serious comorbid systemic disorder incompatible with the study.
- Second primary malignancy (except in situ carcinoma of the cervix, adequately treated basal cell carcinoma of the skin, T1 vocal cord cancer in remission, or prior malignancy treated more than 5 years prior to enrollment without recurrence).
- Pregnancy
Key Trial Info
Start Date :
November 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03791151
Start Date
November 1 2018
End Date
November 30 2019
Last Update
January 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University's Hospital
Cairo, Egypt, 11566